


# MMV-supported projects



MMV Board of Directors/Executive Committee/Financial Audit Committee

## Target product profiles (TPPs)

- 3-day cure, artemisinin-based combination therapies (TPP1)
- Non-artemisinin therapy for uncomplicated malaria treatments and resistance management (TPP1)
- Intermittent preventive treatment (TPP1)
- Severe malaria treatment/pre-referral intervention (TPP1)
- Products targeting prevention of relapse for *P. vivax* (TPP1)
- Chemoprophylaxis (TPP2)

Brand names: 1. Coartem® *Dispersible*; 2. Artesun®; 3. Larinate® 60 mg; 4. Eurartesim®; 5. Pyramax® tablets or granules; 6. ASAQ Winthrop®; 7. SPAQ-CO™; 8. Supyra®; 9. 100 mg Artesunate Rectocaps; 10. Artacap™; 11. *Krintafel/Kozenis* (Trademarks owned or licensed by GSK); 12. Wiwal®

## Target candidate profiles (TCPs)

- Asexual blood stages (TCP 1)
- Relapse prevention (TCP 3)
- Causal prophylaxis (TCP 4)
- Transmission reduction (TCP 5, 6)
- Paediatric formulation
- WHO prequalified OR approved/positive opinion by regulatory bodies who are ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) members/observers
- Via a bioequivalence study
- (-) Past partners are in brackets

\* ERP: Global Fund Expert Review Panel

\*\* MORU: Mahidol Oxford Tropical Medicine Research Unit